EDEN PRAIRIE, Minn.,
March 4, 2022 /PRNewswire/
-- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)
("NeuroOne" or the "Company"), a medical technology company focused
on improving surgical care options and outcomes for patients
suffering from neurological disorders today announced that,
effective March 1, 2022, the
Compensation Committee of the Board of Directors approved an equity
award under the NeuroOne Medical Technologies Corporation 2021
Inducement Plan (the "Inducement Plan"), as a material inducement
to an individual entering into employment with the Company. The
equity award was approved in accordance with Nasdaq Listing Rule
5635(c)(4), which also requires a public announcement of awards
that are not made under a stockholder approved equity
plan.
In connection with entering into employment with NeuroOne, the
individual, who was not previously an employee or director
of NeuroOne, received an option to purchase 10,000 shares of
the Company's common stock. The option award has an exercise price
of $1.95 per share, the closing price of NeuroOne's common
stock on March 1, 2022, the date of the grant. The option has
a ten-year term and vests as to 25% on March
1, 2023, with the remaining shares vesting in equal monthly
installments on the last day of each month over the next thirty-six
(36) months, provided the new hire's employment is continuing on
each such date.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental
stage company committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and
ablation solutions for patients suffering from epilepsy,
Parkinson's disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders
that may improve patient outcomes and reduce procedural costs. For
more information, visit https://www.n1mtc.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301494957.html
SOURCE NeuroOne Medical Technologies Corporation